IRON Key Statistics, Chart & Performance
The current stock price of IRON is 78.29 USD. In the past month the price decreased by -16.14%. In the past year, price increased by 22.67%.
IRON Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About IRON
Company Profile
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Company Info
DISC MEDICINE INC
321 Arsenal Street, Suite 101
Watertown MASSACHUSETTS US
Employees: 84
Phone: 16176749274
DISC MEDICINE INC / IRON FAQ
Can you describe the business of DISC MEDICINE INC?
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Can you provide the latest stock price for DISC MEDICINE INC?
The current stock price of IRON is 78.29 USD. The price decreased by -2.54% in the last trading session.
Does DISC MEDICINE INC pay dividends?
IRON does not pay a dividend.
How is the ChartMill rating for DISC MEDICINE INC?
IRON has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is DISC MEDICINE INC (IRON) stock traded?
IRON stock is listed on the Nasdaq exchange.
When does DISC MEDICINE INC (IRON) report earnings?
DISC MEDICINE INC (IRON) will report earnings on 2026-02-25, after the market close.
What is the ownership structure of DISC MEDICINE INC (IRON)?
You can find the ownership structure of DISC MEDICINE INC (IRON) on the Ownership tab.
IRON Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to IRON. When comparing the yearly performance of all stocks, IRON is one of the better performing stocks in the market, outperforming 84.71% of all stocks.
IRON Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IRON. The financial health of IRON is average, but there are quite some concerns on its profitability.
IRON Financial Highlights
Over the last trailing twelve months IRON reported a non-GAAP Earnings per Share(EPS) of -5.35. The EPS decreased by -36.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.73% | ||
| ROE | -31.59% | ||
| Debt/Equity | 0.05 |
IRON Forecast & Estimates
19 analysts have analysed IRON and the average price target is 121.3 USD. This implies a price increase of 54.93% is expected in the next year compared to the current price of 78.29.